7/27/2019 JOURNAL Breast Cancer
1/10
This Provisional PDF corresponds to the article as PDF and full text (HTML) versions
MiR-34b is associated with clinical outcopatien
Diagnostic Pathology2012,7:31
Marek Svoboda (msvo
Diagnostic Pathology
mailto:[email protected]:[email protected]7/27/2019 JOURNAL Breast Cancer
2/10
MiR-34b is associated with clini
negative breast cancer patients
Marek Svoboda,Aff1
Corresponding Affiliation: Aff1
Email: [email protected]
Jiri Sana,Aff1
Email: [email protected]
7/27/2019 JOURNAL Breast Cancer
3/10
Methods
Thirty-nine TNBC patients with available formalin
were enrolled in the study. MiR-34a, miR-34b, an
and correlated to clinico-pathological features of T
Results
Expression levels of miR-34b significantly correla
(p = 0.0020, log-rank test) and overall survival (OSi h i ifi i i b
7/27/2019 JOURNAL Breast Cancer
4/10
can be used to predict a therapeutic response and c
rationalize treatment decisions.
MicroRNAs (miRNAs) are highly conserved, sma
length, that act as posttranscriptional regulators of
targets. Recent studies showed that miRNAs regul
tumor suppressor genes, and genes associated with
chemoresistance of tumors. Therefore, these mole
pathogenesis of many cancers, including the breas
[8,9]. Many recent works described that the gene pmutations in TNBC patients activates transcriptio
7/27/2019 JOURNAL Breast Cancer
5/10
T
1 10
2 21
3 4
4 4
N
0 17
1 13
2 7
7/27/2019 JOURNAL Breast Cancer
6/10
the Taq-Man MicroRNA Assay protocol (Applied
performed using the Applied Biosystems 7500 Re
the TaqMan MicroRNA Assay protocol. Reverse tdetection were carried out using hsa-miR-34a, hsa
4427975; Applied Biosystems, USA). RNU6B (A
USA) was used as a reference gene. The threshold
default threshold settings.
Statistical analysis
Statistical analysis of differences of miRNA expre
7/27/2019 JOURNAL Breast Cancer
7/10
view, it is one of the features of TNBCs that is poo
expression could also be a marker of differentiatio
assumption is also supported by the fact that miR-direct regulator of Notch2 which plays an importa
decreased in breast cancer tumors with poor differ
[20]. In breast cancer, Notch2 pathway is also a po
effect on tumor growth in xenograft model [21]. R
revealed that overexpression of another member o
an aggressive breast tumor phenotype (positive no
rate, high grade, p53-positivity) [22]. Moreover, D
miR-34a significantly suppressed proliferation of M
7/27/2019 JOURNAL Breast Cancer
8/10
References
1. Bertos NR, Park M: Breast cancer - one term
121:37893796.
2. Voduc KD, Cheang MC, Tyldesley S, Gelmon
cancer subtypes and the risk of local and region
1691.
3. Lee DS, Kim SH, Suh YJ, Kim S, Kim HK, Sh
7/27/2019 JOURNAL Breast Cancer
9/10
14. Hiroki E, Suzuki F, Akahira JI, Nagase S, Ito
H, Yaegashi N: MicroRNA-34b functions as a p
serous adenocarcinoma.Int J Cancer2012, in pr
15. Lee YM, Lee JY, Ho CC, Hong QS, Yu SL, T
MicroRNA 34b as a tumor suppressor in estrog
cells.Breast Cancer Res2011, 13:R116.
16. Katada T, Ishiguro H, Kuwabara Y, Kimura M
Fujii Y: microRNA expression profile in undiffe
2009 34:537542
7/27/2019 JOURNAL Breast Cancer
10/10Figure 1